Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Profit After Tax (2017 - 2025)

Historic Profit After Tax for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$36.8 million.

  • Dianthus Therapeutics' Profit After Tax fell 4604.35% to -$36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.4 million, marking a year-over-year decrease of 8825.84%. This contributed to the annual value of -$85.0 million for FY2024, which is 9495.41% down from last year.
  • Dianthus Therapeutics' Profit After Tax amounted to -$36.8 million in Q3 2025, which was down 4604.35% from -$31.6 million recorded in Q2 2025.
  • Dianthus Therapeutics' Profit After Tax's 5-year high stood at -$7.1 million during Q1 2023, with a 5-year trough of -$36.8 million in Q3 2025.
  • Moreover, its 4-year median value for Profit After Tax was -$14.8 million (2023), whereas its average is -$18.8 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Profit After Tax plummeted by 495.05% in 2023, and later crashed by 16859.43% in 2024.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Profit After Tax stood at -$10.1 million in 2022, then dropped by 4.95% to -$10.6 million in 2023, then tumbled by 168.59% to -$28.5 million in 2024, then fell by 29.13% to -$36.8 million in 2025.
  • Its Profit After Tax stands at -$36.8 million for Q3 2025, versus -$31.6 million for Q2 2025 and -$29.5 million for Q1 2025.